Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Stoppa

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
American Journal of Human Genetics|May 1, 1997
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer GroupD Stoppa-Lyonnet, P Laurent-Puig, L Essioux, et al.
Journal of Medical Genetics|May 31, 2008
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS familiesG Bougeard, R Sesboüé, S Baert-Desurmont, et al.
British Journal of Cancer|March 7, 2013
Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancerA Brédart, J L Kop, A Depauw, et al.
Cancer Research|May 1, 1998
Mutations at BRCA1: the medullary breast carcinoma revisitedF Eisinger, J Jacquemier, C Charpin, et al.
Familial Cancer|September 16, 2010
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanomaB Buecher, M Gauthier-Villars, L Desjardins, et al.
Gynecologic Oncology Reports|September 20, 2021
Tumor <i>BRCA</i> testing can reveal a high tumor mutational burden related to <i>POLE</i> pathogenic variantsM-C Villy, J Masliah-Planchon, S Melaabi, et al.
Lancet (London, England)|December 29, 2000
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study GroupS A Narod, J S Brunet, P Ghadirian, et al.
American Journal of Medical Genetics|October 27, 1998
Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le CancerL Essioux, C Girodet, O Sinilnikova, et al.
Neurogenetics|May 15, 2009
Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical managementM Anheim, M Fleury, B Monga, et al.
Annales D'Endocrinologie|April 6, 1999
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]F Eisinger, N Alby, A Bremond, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
American Journal of Human Genetics|May 1, 1997
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer GroupD Stoppa-Lyonnet, P Laurent-Puig, L Essioux, et al.
Journal of Medical Genetics|May 31, 2008
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS familiesG Bougeard, R Sesboüé, S Baert-Desurmont, et al.
British Journal of Cancer|March 7, 2013
Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancerA Brédart, J L Kop, A Depauw, et al.
Cancer Research|May 1, 1998
Mutations at BRCA1: the medullary breast carcinoma revisitedF Eisinger, J Jacquemier, C Charpin, et al.
Familial Cancer|September 16, 2010
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanomaB Buecher, M Gauthier-Villars, L Desjardins, et al.
Gynecologic Oncology Reports|September 20, 2021
Tumor <i>BRCA</i> testing can reveal a high tumor mutational burden related to <i>POLE</i> pathogenic variantsM-C Villy, J Masliah-Planchon, S Melaabi, et al.
Lancet (London, England)|December 29, 2000
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study GroupS A Narod, J S Brunet, P Ghadirian, et al.
American Journal of Medical Genetics|October 27, 1998
Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le CancerL Essioux, C Girodet, O Sinilnikova, et al.
Neurogenetics|May 15, 2009
Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical managementM Anheim, M Fleury, B Monga, et al.
Annales D'Endocrinologie|April 6, 1999
[INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer]F Eisinger, N Alby, A Bremond, et al.
Pageof 10